An intravenous, next-generation proteasome inhibitor for third-line treatment of multiple myeloma.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
An intravenous, next-generation proteasome inhibitor for third-line treatment of multiple myeloma.
If you have a Hayes login, click here to view the full report on the Knowledge Center.